

# VIRTUAL MEETING INVITATION

NORDIC | Tuesday 7<sup>th</sup> of September 2021 | 15:00 - 17:00

## A CLINICAL DIALOGUE FROM A SURGICAL PERSPECTIVE ON THE EXPANDING ROLE OF IMMUNOTHERAPY IN NON-MELANOMA SKIN CANCER (NMSC)

Join this interactive expert meeting and get updated on patient selection & treatment, discussed and presented with relevant patient cases.

The focus in this interactive meeting is not only the new opportunities immunotherapy brings to the treatment paradigm of NMSC, but also on patient selection and treatment modality, from a surgical perspective.

**When is surgery the best option and when is it not?**



### AGENDA

- 15.00 - 15.05** Welcome and intro by *Sanofi Genzyme*
- 15.05 - 15.25** Immune checkpoint inhibition for non-melanoma skin cancer: What's new? An update from ASCO with patient case. *Prof. Axel Hauschild*
- 15.25 - 15.45** Surgery vs immunotherapy: when is surgery the best option and when is it not? Patient case, implications for practice & treatment choice. *Prof. Andreas Dietz*
- 15.45 - 16.45** Patient cases from Sweden *Mathias von Beckerath*, Norway *Truls Ryder*, Denmark *Lars Stolle*
- 16.45 - 17.00** Q&A: How do we find the best route for our patients? Concluding remarks by *Prof. Axel Hauschild*

**SIGN UP BY THIS LINK: [HTTPS://BIT.LY/3GBJTOO](https://bit.ly/3GBJTOO)**

### CHAIR AND SPEAKER



#### Prof. Dr. med. Axel Hauschild

Professor of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany

Prof. Dr. med. Axel Hauschild is Head of the Skin Cancer Working Group at the University Hospital Schleswig-Holstein, Campus Kiel, Germany. His main clinical interests are the diagnosis and treatment of melanoma and non-melanoma skin cancer.

He has been the principal investigator of more than 100 phase 1-3 clinical trials on melanoma, cutaneous lymphomas and epithelial skin cancers. Professor Hauschild was the congress president of the 8<sup>th</sup> World Congress on Melanoma in Hamburg (2013) and is the designated president of the 10<sup>th</sup> World Congress on Melanoma in April 2021 in Rome/Italy.

He has been invited as a speaker to more than 700 conferences across the world. Professor Hauschild has published over 420 articles in peer-reviewed journals such as the New England Journal of Medicine, Lancet, Lancet Oncology and Journal of Clinical Oncology.

### SPEAKER



#### Prof. Dr. Andreas Dietz

Director ENT Department, University hospital of Leipzig

Since 2004 Andreas Dietz has been the director of the ENT Department, University hospital of Leipzig. He is an ENT and Head and Neck surgeon and are responsible for the treatment of CSCC patients.

Professor Dietz is the President of the German ENT-Society (DGHNO-KHC) and elected member of the board of directors of European Head and Neck Society (EHNS) since 2018.

He is the author/co-author of more than 360 pub-med listed peer reviewed papers.

### SPEAKER



#### MD. PhD Mathias von Beckerath

Dept. of Otorhinolaryngology, Head and Neck Surgery, Karolinska University Hospital, Stockholm, Sweden

Mathias von Beckerath, MD. PhD has a 15 year experience in Head and Neck surgery. His practice also includes advanced cutaneous malignancies in the head and neck area including care of the regional spreading tumors in close cooperation with plastic surgeons and oncologists. He has taken part in creation of the first Swedish national guidelines for cSCC and is a member of the board of the Swedish ENT-Head and neck society.

### SPEAKER



#### Prof. Truls Ryder

Chief attending Oncologic Plastic Surgery, Oslo University Hospital Norway

Dr. Ryder has been treating skin malignancies for the past 25 years as well as responsible for reconstructive procedures related to gastro-, orthopedic- and gynecological cancers at the Radium hospital/OUS. Former microsurgery fellowship training at the MD Anderson Cancer Hospital. Member of the Norwegian Melanoma Group.

### SPEAKER



#### MD. PhD Lars Stolle

Plastic and Breast Surgery, Aarhus University Hospital Denmark

Lars Bjørn Stolle, Consultant, MD, PhD, ass prof., Plastic- and Reconstructive Surgeon at Aarhus University Hospital with over 10 y experience in treating advanced skin carcinomas and malignant melanoma/board member of the Danisch Melanoma Group. Over 50 international/national publications, supervisor of PhD-students and thesis students. Designer of information - and animation videos for cancer patients.

**SIGN UP BY THIS LINK: [HTTPS://BIT.LY/3GBJTOO](https://bit.ly/3GBJTOO)**

**TO RECEIVE INVITATIONS AND SCIENTIFIC NEWS FOLLOW THIS LINK: [HTTP://WWW.SANOFI.SE/SV/KONTAKT-HCP](http://www.sanofi.se/sv/kontakt-hcp)**

Mötet följer de regler som gäller enligt avtalet mellan LIF och Sveriges Kommuner och Regioner. Vi ber dig notera att huvudmans godkännande ska inhämtas före deltagande i mötet. Inbjudan skickas till intresserade inom området som lämnat medgivande till inbjudningar och uppdateringar.

MAT-SE-2100723(V 1.0)Jun 2021

Sanofi and Regeneron are collaborating in the global development and commercialization for LIBTAYO® (cemiplimab).

© 2020 Sanofi and Regeneron Pharmaceuticals, Inc. All rights reserved.

Sanofi AB | Box 30052 | 104 25 Stockholm | Telefon 08-634 50 00 | infoavd@sanofi.com | www.sanofi.se | www.libtayo.se

SANOFI GENZYME | REGENERON